IPP Bureau
FDA approves Roche’s Itovebi for treatment of HER2-negative breast cancer with a PIK3CA mutation
By IPP Bureau - October 11, 2024
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Privi Speciality Chemicals gets USFDA certificate for camphor product
By IPP Bureau - October 11, 2024
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
OneSource unveils new brand identity at CPHI Milan
By IPP Bureau - October 11, 2024
Aims to achieve CDMO sales of US$ 400 million by 2028
WHO declares India has eliminated Trachoma as a public health problem in 2024
By IPP Bureau - October 10, 2024
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh
By IPP Bureau - October 10, 2024
We now rank 3rd in pharmaceutical production by volume and 14th by value
Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries
By IPP Bureau - October 09, 2024
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Aurigene Oncology gets positive results of Phase 1 study for CAR-T cell therapy for multiple myeloma
By IPP Bureau - October 09, 2024
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia
By IPP Bureau - October 09, 2024
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Vestige Marketing launches two innovative products
By IPP Bureau - October 09, 2024
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
By IPP Bureau - October 09, 2024
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Aster implements India’s first IOeRT for cancer care
By IPP Bureau - October 09, 2024
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
By IPP Bureau - October 09, 2024
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
By IPP Bureau - October 08, 2024
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Davaindia accelerates expansion with 1,165 operational stores
By IPP Bureau - October 08, 2024
Strategic focus on COCO-model with a nationwide reach of 501 stores
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
By IPP Bureau - October 08, 2024
CSPC will receive an upfront payment of $100 million from AstraZeneca
